Physician-modified Endovascular Graft for Repair of Complex Thoracoabdominal and Abdominal Aortic Aneurysms

Last updated: January 3, 2025
Sponsor: Medstar Health Research Institute
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Aneurysm

Cardiovascular Disease

Heart Disease

Treatment

Physician-Modified Cook Zenith Alpha Thoracic Endovascular Graft

Clinical Study ID

NCT04526938
FEVAR
  • Ages > 18
  • All Genders

Study Summary

The primary objective of this study is to assess the use of a physician-modified Cook Alpha Thoracic Endovascular Graft in the repair of complex aortic aneurysms and thoracoabdominal aortic aneurysms and aneurysms secondary to aortic dissections in high-risk patients having appropriate anatomy. The primary intent of the study is to assess the safety and preliminary effectiveness of the device. Additionally, the study will assess renal function, radiation exposure, and quality of life.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥ 18 years old

  2. Life expectancy > 2 year(s)

  3. Patient is considered to be at high risk of morbidity and mortality with opensurgical repair

  4. A patient may be entered into the study if the patient has at least one of thefollowing:

  • Juxtarenal, suprarenal or a thoracoabdominal aortic aneurysm with a diameter ≥ 5.5 cm or 2 times the normal aortic diameter

  • Aneurysm with a history of growth ≥ 0.5 cm per year

  • Saccular aneurysms deemed at significant risk for rupture based upon physicianinterpretation

  • Symptomatic juxtarenal, suprarenal or a thoracoabdominal aortic aneurysm

  • Thoracoabdominal aortic aneurysms secondary to aortic dissection meeting abovecriteria

  1. Patient is considered to be at high risk of morbidity and mortality with opensurgical repair

  2. Iliac or femoral access vessel morphology that is compatible with vascular accesstechniques, devices or accessories, with or without use of a surgical conduit

  3. Nonaneurysmal aortic segment proximal to the aneurysm (neck) with a:

  • Minimum neck length of 20mm

  • Diameter in the range of 21-38mm

  • Angle less than 60° relative to the axis of the aneurysm

  • Angle less than 60° relative to the axis of the suprarenal aorta

  1. Minimum branch vessel diameter greater than 5 mm

  2. Iliac artery distal fixation site greater than 10mm in length and diameter in therange of 8-21mm.

Exclusion

Exclusion Criteria:

  1. Under the age of 18 years

  2. Can be treated in accordance with the instructions for use with a legally marketedendovascular prosthesis

  3. Is eligible for enrollment in a manufacturer-sponsored IDE at the investigationalsite

  4. Willing to participate in a sponsor-investigator IDE with access to a non-physicianmodified endovascular prostheses at the investigational site

  5. Willing to travel to an investigational site with access to a non-physician modifiedendovascular prosthesis

  6. Unwilling or unable to comply with the follow-up schedule

  7. Inability or refusal to give informed consent by patient or legal representative

  8. Patient is pregnant or breastfeeding

  9. Life expectancy < 2-years despite successful aneurysm exclusion

  10. Free rupture with hemodynamic instability

  11. Ongoing infection

  12. Diagnosis of, or suspected connective tissue disease

  13. Known sensitivities or allergies to the materials of construction of the devices

  14. Known hypersensitivity or contraindication to anticoagulation or contrast media thatcannot be adequately medically managed

  15. Uncorrectable coagulopathy

  16. Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safecapacity of the equipment

  17. Patient has had a major surgical or interventional procedure unrelated to thetreatment of the aneurysm planned ≤ 30 days of the endovascular repair

  18. Unstable angina (defined as angina with a progressive increase in symptoms, newonset at rest or nocturnal angina)

  19. Systemic or local infection that may increase the risk of endovascular graftinfection

  20. Leaking or free rupture of aneurysm associated with hemodynamic instability.

  21. Baseline creatinine greater than 3.0 mg/dL

  22. Known history of, or suspected connective tissue disorders (e.g., Marfan Syndrome,Ehler's Danlos Syndrome)

Anatomical exclusion criteria:

  1. Inadequate femoral or iliac access compatible with the required delivery systems,not amenable to open surgical or endovascular conduit placement

  2. Absence of a non-aneurysmal aortic segment for proximal seal zone with:

  • A diameter measured outer wall to outer wall of no greater than 38mm and noless than 21 mm;

  • Parallel aortic wall with <20% diameter change and without significantcalcification and/or thrombus in the selected area of seal zone

  1. Visceral vessel anatomy not compatible with physician-modified Zenith® AlphaEndovascular Graft due to excessive occlusive disease or small size not amenable tostent graft placement

  2. Unsuitable distal iliac artery fixation site and anatomy:

  • Common iliac artery fixation site diameter measured outer wall to outer wall ona sectional image (CT) <8.0 mm with inability to perform open surgical conduit

  • Iliac artery diameter measured outer wall to outer wall on a sectional image (CT) >21 mm at distal fixation site, with inability to perform open internaliliac artery revascularization or iliac branch stent graft

  • Iliac artery distal fixation site <10 mm in length

  • Inability to preserve at least one hypogastric artery

Study Design

Total Participants: 200
Treatment Group(s): 1
Primary Treatment: Physician-Modified Cook Zenith Alpha Thoracic Endovascular Graft
Phase:
Study Start date:
September 20, 2021
Estimated Completion Date:
September 30, 2028

Study Description

This study is a prospective, single-center, non-randomized, single-arm study. Each enrolled subject will undergo periodic follow-up evaluations involving physical exams, computed tomography angiography (CTA) of chest, abdomen and pelvis, abdominal duplex ultrasound, creatinine measurement, quality of life questionnaire at specific, protocol-defined intervals for a period of five years following the physician-modified Cook Zenith® Alpha Endovascular Graft implant.

Connect with a study center

  • MedStar Washington Hospital Center

    Washington, District of Columbia 20010
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.